Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p>Fitness costs are key determinants of whether drug resistance alleles establish and how fast they spread within populations. More than 125 different <jats:italic>kelch13</jats:italic> alleles, each containing a different amino acid substitution, have arisen in Southeast Asian malaria parasite (<jats:named-content content-type="genus-species">Plasmodium falciparum</jats:named-content>) populations under artemisinin selection over the past 15 years in a dramatic example of a soft selective event. However, just one of these alleles (C580Y) is now outcompeting other alleles in multiple different countries and is spreading toward fixation. Here we examine the fitness consequences of C580Y, relative to another less successful <jats:italic>kelch13</jats:italic> mutation (R561H), to try to explain the distinctive dynamics of C580Y. We hypothesized that C580Y will show lower fitness costs than other <jats:italic>kelch13</jats:italic> substitutions in the absence of artemisinin treatment. We used CRISPR/Cas9 methods to introduce single mutations (C580Y or R561H) or synonymous control edits into a wild-type parasite isolated on the Thailand-Myanmar border, conducted replicated head-to-head competition assays, and determined the outcome of competition using deep sequencing of <jats:italic>kelch13</jats:italic> amplicons. Contrary to our predictions, these experiments reveal that C580Y carries higher fitness costs (<jats:italic>s</jats:italic> [selection coefficient] = 0.15 ± 0.008 [1 standard error {SE}]) than R561H (<jats:italic>s</jats:italic> = 0.084 ± 0.005). Furthermore, R561H outcompetes C580Y in direct competition (<jats:italic>s</jats:italic> = 0.065 ± 0.004). We conclude that fitness costs of C580Y in isolation are unlikely to explain the rapid spread of this substitution.</jats:p>

Original publication





Antimicrobial Agents and Chemotherapy


American Society for Microbiology

Publication Date